US Patent

US7741358 — Crystal form of asenapine maleate

Method of Use · Assigned to Organon NV · Expires 2026-04-06 · 0y expired

Vulnerability score 65/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects an orthorhombic crystal form of asenapine maleate and methods for preparing and using it in pharmaceutical compositions.

USPTO Abstract

The invention relates to an orthorhombic crystal form of compound trans-5-chloro-2,3,3a,12b-tetrahydro-2-methyl-1H-dibenz [2,3:6,7]oxepino[4,5-c]pyrrole (Z)-2-butenedioate, to methods for the preparation of this crystal form and to pharmaceutical compositions comprising an orthorhombic crystal form.

Drugs covered by this patent

asenapine-maleate (ASENAPINE MALEATE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1966`	—	asenapine-maleate
`U-1960`	—	asenapine-maleate
`U-1963`	—	asenapine-maleate

Patent Metadata

Patent number: US7741358
Jurisdiction: US
Classification: Method of Use
Expires: 2026-04-06
Drug substance claim: Yes
Drug product claim: Yes
Assignee: Organon NV
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.